Investor expectations, fueled by promises of genetic breakthroughs, are at an all-time high. Markets segmented by genetics-based diagnoses and rising demand for individualized care will soon make their mark on the industry's dominant blockbuster strategy. Rather than losing sleep over that, pharmaceutical executives can secure competitive advantage by capitalizing on the combination of consumers' rising power, increased access to information, and rejection of one-size-fits-all treatment regimens.
FDA has issued the industry a new charge-pay closer attention to risk management. Now that prescription drug user fees have helped the agency approve candidates more rapidly, FDA has returned to its basic mandate: assuring that marketed pharmaceuticals are safe. In the past, that meant clear labeling with adequate directions and warnings based on clinical trials. The agency now believes that product safety extends beyond warning labels and wants to ensure that prescriptions are used safely as well. As a result, it is asking the pharma industry to demonstrate products' safety before approval and to further control their use after
No one wants to hang around people who are sad all the time, or who have a chip on their shoulder.
Consumer outrage at daily reports of new financial scandals creates a dangerous environment for corporate reputations, but pharma companies can turn the public's low opinion-and questions about rising drug prices-to their advantage if they work systematically to build long-term trust.
In the world of pharmaceutical names, the trademark has always been the star, and every other word has played a supporting role. But recent developments at FDA-and the industry's response to those developments-have set the stage for a new approach to nomenclature.
See how you can incorporate these five B's in some of your two-minute-or-less encounters with physicians.
t's 4 pm on Friday. The board of directors has just made an important decision and wants to announce it over the weekend. The challenge? Publish an English-language version on the company's global Web portals immediately. The problem? It's the weekend and offices around the world are about to close. In the past, that meant hunkering down for a weekend of e-mails to coordinate the effort, but now there is a better solution. After writing the document in Microsoft Word, the sender simply clicks on a special menu item, "Publish to Portals," and off it goes. Confirming dialogue boxes allow
Industry Must Set Product Prices That Ensure Reasonable Profit - and Minimize Political Fallout
Partnerships between pharmaceutical (Rx) and diagnostic (Dx) companies are difficult to achieve because most managers don't understand what it takes to make them work.
Uncertainty swirls on just how effective policy competition between the EU and UK on these much-needed products will be.
No greater challenge faces any writer than the empty page. To sully that beautiful white space with mere words can seem so arrogant, so pretentious, that one's urge is to leave it alone, in perfect blankness. To paraphrase an old writer's adage, just to begin may require lowering your standards-an act salvaged later only by careful editing.
The global pain market will reach nearly $29.8 billion in 2008, of which $21.8 billion will come from the United States.
Physicians say they are now much more likely to limit their time and dialogue with sales representatives … except for a few individuals who take a different approach.
Stan Bernard outlines the seven ways for pharmas to ensure successful execution of action steps following brand ‘war games’.
The populist-driven shifts trumpeted from the US to the EU leaves plenty of question marks when trying to size up the trajectory of the global pharma industry. One certainty, however, will be change.
Pharmaceutical companies are awash in a sea of compliance regulations that affect their business operations both inside and outside the US.
Analysis shows that persistence is paying off for drug developers, driven by the rise of CAR-T and other gene therapy, newly discovered cancer targets, better patient identification methods-and the realization that failures have their place in shaping the pipeline of tomorrow.
Inter Partes Review can potentially offer a more economical and streamlined litigation strategy for pharma and biotech players, writes David Dalke.
Compliance with the new traceability requirements necessitates an understanding of how and when to begin implementing changes in an ever-evolving industry.
Is crowdfunding an attractive alternative to finance pharma and biotech start-ups? Seth R. Ogden and M. Andrew Holtman report.
Is crowdfunding an attractive alternative to finance pharma and biotech start-ups? Seth R. Ogden and M. Andrew Holtman report.
Defining the critical coaching steps necessary for top managers to realize their potential in an industry undergoing significant restructuring of human and financial capital.
As the UK exits the European Union, the pharmaceutical and life sciences industries should prepare for changes by identifying key business issues, mitigating risks and creating plans for multiple scenarios.
New research on the role of microbes in fighting disease is transforming the way medicine views bacteria, writes Lee Jones.